8-K
0001484612false00014846122024-02-162024-02-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 16, 2024

Outset Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39513

20-0514392

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

3052 Orchard Dr.,

San Jose, California

95134

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (669) 231-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

OM

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 

Item 2.02 Result of Operations and Financial Condition.

 

On February 21, 2024, Outset Medical, Inc. (the “Company”) issued a press release and will hold its fourth quarter and full year 2023 earnings conference call announcing the Company’s financial results for the quarter and year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

 

The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 16, 2024, Steve Williamson informed the Company of his decision to depart from the Company and his role as Chief Commercial Officer, effective March 1, 2024, to become the CEO of another publicly traded medical device company. Mr. Williamson’s departure is not due to any dispute or disagreement with the Company or its management.

 

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

Description

99.1

Press Release entitled “Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results” dated February 21, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Outset Medical, Inc.

 

Date: February 21, 2024

By:

/s/Nabeel Ahmed

Nabeel Ahmed

Chief Financial Officer

 

 


EX-99.1

Exhibit 99.1

 

 

Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results

San Jose, CA – February 21, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter, Year-End Results, and Recent Highlights

Recorded net revenue of $30.5 million in the fourth quarter, bringing 2023 revenue to $130.4 million, a 13% increase compared to $115.4 million in 2022.
Increased gross margin in the fourth quarter by nearly 900 basis points from the prior-year period. Fourth quarter gross margin reached 25.3% (26.7% on a non-GAAP basis) compared to 16.5% (17.1% on a non-GAAP basis) in the fourth quarter of 2022. Gross margin for the full year was 22.2% (23.6% on a non-GAAP basis) compared to 15.5% (16.1% on a non-GAAP basis) in 2022.
As previously reported, recurring revenue consisting of Tablo consumables and services, exceeded 50% of total revenue in 2023, and the Tablo installed base reached 5,350 consoles exiting 2023, including approximately 4,050 with acute- and sub-acute care providers and 1,300 with home providers.

“As we announced in January, our results for the fourth quarter and full year reflect the scale we have built in the acute setting and progress we are making to expand Tablo’s use at home, with our growth in both end markets contributing to a 34% increase in the Tablo installed base and nearly 50% growth in consumable revenue,” said Leslie Trigg, Chair and Chief Executive Officer of Outset. “We exited 2023 with a record 50% recurring revenue, fourth-quarter gross margin expanding nearly 9 percentage points, and a strong balance sheet to continue to fund our growth. We are proud of the difference Tablo and our team made in 2023 to help providers save substantially on the cost to deliver life-sustaining dialysis, and patients regain control that has been historically lost with their diagnosis.”

Fourth Quarter 2023 Financial Results

Revenue for the fourth quarter of 2023 was $30.5 million, representing a decrease of 4.7% compared to $32.0 million in the fourth quarter of 2022. Product revenue was $22.9 million, representing a decrease of 13.2% compared to $26.4 million in the fourth quarter of 2022. Service and other revenue was $7.6 million, representing an increase of 34.9% compared to $5.6 million in the fourth quarter of 2022.

Total gross profit was $7.7 million, compared to $5.3 million for the fourth quarter of 2022. Total gross margin was 25.3%, compared to 16.5% in the fourth quarter of 2022. On a non-GAAP basis, gross margin improved to 26.7% from 17.1% in the fourth quarter of 2022. Product gross profit was $8.3 million, compared to $4.3 million of product gross profit in the fourth quarter of 2022. Product gross margin was 36.3%, compared to 16.4% in the fourth quarter of 2022. Service and other gross loss was ($0.6) million, compared to $1.0 million of service and other gross profit in the fourth quarter of 2022. Service and other gross margin was (7.8)%, compared to 17.0% in the fourth quarter of 2022.

Operating expenses were $45.1 million, including research and development (R&D) expenses of $12.5 million, sales and marketing (S&M) expenses of $22.2 million, and general and administrative (G&A) expenses of $10.3 million. This compared to operating expenses of $45.1 million, including R&D expenses of $11.4 million, S&M expenses of $23.6 million, and G&A expenses of $10.0 million in the fourth quarter of 2022.

Excluding stock-based compensation expense, non-GAAP operating expenses were $36.4 million, including R&D expenses of $10.2 million, S&M expenses of $19.7 million, and G&A expenses of $6.5 million.

Net loss was ($38.6) million, or ($0.77) per share, compared to net loss of ($41.4) million, or ($0.86) per share, for the same period in 2022. On a non-GAAP basis, net loss was ($29.5) million, or ($0.59) per share, compared to non-GAAP net loss of ($34.1) million, or ($0.71) per share for the same period in 2022.

Total cash, including restricted cash, cash equivalents and short-term investments, was $206.7 million as of December 31, 2023, compared to $290.8 million as of December 31, 2022.

Full Year 2023 Financial Results

 


 

Revenue for 2023 was $130.4 million, representing an increase of 13.0% compared to $115.4 million for 2022. Product revenue was $103.5 million, representing an increase of 10.9% compared to $93.4 million for 2022. Service and other revenue was $26.8 million, representing an increase of 22.1% compared to $22.0 million for 2022.

Total gross profit was $29.0 million, compared to $17.8 million for 2022. Total gross margin was 22.2%, compared to 15.5% in 2022. On a non-GAAP basis, gross margin improved to 23.6% from 16.1% in 2022. Product gross profit was $29.1 million, compared to $10.9 million of product gross profit in 2022. Product gross margin was 28.1%, compared to 11.6% in 2022. Service and other gross loss was ($0.1) million, compared to $7.0 million of service and other gross profit in 2022. Service and other gross margin was (0.3)%, compared to 31.6% in 2022.

Operating expenses were $198.8 million, including R&D expenses of $57.3 million, S&M expenses of $96.2 million, and G&A expenses of $45.2 million. This compared to operating expenses of $178.9 million, including R&D expenses of $48.9 million, S&M expenses of $89.5 million, and G&A expenses of $40.5 million for 2022.

Excluding stock-based compensation expense, non-GAAP operating expenses were $161.9 million, including R&D expenses of $46.8 million, S&M expenses of $83.8 million, and G&A expenses of $31.4 million.

Net loss was ($172.8) million, or ($3.48) per share, compared to a net loss of ($163.0) million, or ($3.38) per share, for 2022. On a non-GAAP basis, net loss was ($134.2) million, or ($2.70) per share, compared to a non-GAAP net loss of ($135.8) million, or ($2.82) per share for 2022.

Full Year 2024 Financial Guidance

Outset reaffirmed its previously provided guidance for 2024, including revenue of $145 million to $153 million, growing 12% to 18% over 2023, and non-GAAP gross margin in the low-30% range for 2024, exiting the year in the mid-30% range for the fourth quarter.

Webcast and Conference Call Details

Outset will host a conference call today, February 21, 2024, at 2:00 p.m. PT / 5:00 p.m. ET to discuss its fourth quarter and full year 2023 financial results. Those interested in listening to the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

The Company may report non-GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company’s financial measures under GAAP include stock-based compensation expense, as listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release. Management has excluded the effects of this non-cash expense item in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations

 


 

regarding projected revenues, gross margin, operating expenses, capital expenditures, profitability and outlook; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to expand gross margins; the Company’s ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner; as well as the Company’s expectations regarding the impact of macroeconomic factors on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Investor Contact

Jim Mazzola

Vice President, Investor Relations

jmazzola@outsetmedical.com

 

 

 


 

Outset Medical, Inc.

Condensed Statements of Operations

(in thousands, except per share amounts)

(unaudited)

 

 

 

Three Months Ended

 

 

 

Years Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

22,897

 

 

 

$

26,364

 

 

 

$

103,537

 

 

 

$

93,388

 

 

Service and other revenue

 

 

7,610

 

 

 

 

5,643

 

 

 

 

26,839

 

 

 

 

21,987

 

 

Total revenue

 

 

30,507

 

 

 

 

32,007

 

 

 

 

130,376

 

 

 

 

115,375

 

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue (2)

 

 

14,588

 

 

 

 

22,050

 

 

 

 

74,454

 

 

 

 

82,510

 

 

Cost of service and other revenue

 

 

8,207

 

 

 

 

4,684

 

 

 

 

26,922

 

 

 

 

15,032

 

 

Total cost of revenue

 

 

22,795

 

 

 

 

26,734

 

 

 

 

101,376

 

 

 

 

97,542

 

 

Gross profit (1)

 

 

7,712

 

 

 

 

5,273

 

 

 

 

29,000

 

 

 

 

17,833

 

 

Gross margin (1)

 

 

25.3

 

%

 

 

16.5

 

%

 

 

22.2

 

%

 

 

15.5

 

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development (2)

 

 

12,532

 

 

 

 

11,444

 

 

 

 

57,307

 

 

 

 

48,855

 

 

Sales and marketing (2)

 

 

22,194

 

 

 

 

23,631

 

 

 

 

96,232

 

 

 

 

89,482

 

 

General and administrative (2)

 

 

10,339

 

 

 

 

10,022

 

 

 

 

45,231

 

 

 

 

40,515

 

 

Total operating expenses

 

 

45,065

 

 

 

 

45,097

 

 

 

 

198,770

 

 

 

 

178,852

 

 

Loss from operations

 

 

(37,353

)

 

 

 

(39,824

)

 

 

 

(169,770

)

 

 

 

(161,019

)

 

Interest income and other income, net

 

 

2,282

 

 

 

 

1,907

 

 

 

 

10,171

 

 

 

 

3,291

 

 

Interest expense

 

 

(3,417

)

 

 

 

(2,096

)

 

 

 

(12,675

)

 

 

 

(3,566

)

 

Loss on extinguishment of term loan

 

 

 

 

 

 

(1,367

)

 

 

 

 

 

 

 

(1,367

)

 

Loss before provision for income taxes

 

 

(38,488

)

 

 

 

(41,380

)

 

 

 

(172,274

)

 

 

 

(162,661

)

 

Provision for income taxes

 

 

112

 

 

 

 

64

 

 

 

 

523

 

 

 

 

295

 

 

Net loss

 

$

(38,600

)

 

 

$

(41,444

)

 

 

$

(172,797

)

 

 

$

(162,956

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

 

$

(0.77

)

 

 

$

(0.86

)

 

 

$

(3.48

)

 

 

$

(3.38

)

 

Shares used in computing net loss per share, basic and diluted

 

 

50,254

 

 

 

 

48,375

 

 

 

 

49,588

 

 

 

 

48,161

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)  Gross profit and gross margin by source consisted of the following:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Years Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

Gross profit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

8,309

 

 

 

$

4,314

 

 

 

$

29,083

 

 

 

$

10,878

 

 

Service and other revenue

 

 

(597

)

 

 

 

959

 

 

 

 

(83

)

 

 

 

6,955

 

 

Total gross profit

 

$

7,712

 

 

 

$

5,273

 

 

 

$

29,000

 

 

 

$

17,833

 

 

Gross margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

 

36.3

 

%

 

 

16.4

 

%

 

 

28.1

 

%

 

 

11.6

 

%

Service and other revenue

 

 

(7.8

)

%

 

 

17.0

 

%

 

 

(0.3

)

%

 

 

31.6

 

%

Total gross margin

 

 

25.3

 

%

 

 

16.5

 

%

 

 

22.2

 

%

 

 

15.5

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2)  Include stock-based compensation expense as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Years Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

Cost of revenue

 

$

424

 

 

 

$

208

 

 

 

$

1,805

 

 

 

$

701

 

 

Research and development

 

 

2,306

 

 

 

 

1,960

 

 

 

 

10,538

 

 

 

 

6,845

 

 

Sales and marketing

 

 

2,511

 

 

 

 

2,829

 

 

 

 

12,419

 

 

 

 

10,269

 

 

General and administrative

 

 

3,857

 

 

 

 

2,356

 

 

 

 

13,872

 

 

 

 

9,388

 

 

Total stock-based compensation expense

 

$

9,098

 

 

 

$

7,353

 

 

 

$

38,634

 

 

 

$

27,203

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Outset Medical, Inc.

Condensed Balance Sheets

(in thousands, except per share amounts)

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

68,509

 

 

$

73,222

 

Short-term investments

 

 

134,815

 

 

 

214,280

 

Accounts receivable, net

 

 

32,980

 

 

 

28,070

 

Inventories

 

 

49,215

 

 

 

51,476

 

Prepaid expenses and other current assets

 

 

5,700

 

 

 

6,597

 

Total current assets

 

 

291,219

 

 

 

373,645

 

Restricted cash

 

 

3,329

 

 

 

3,311

 

Property and equipment, net

 

 

13,273

 

 

 

15,876

 

Operating lease right-of-use assets

 

 

5,375

 

 

 

6,117

 

Other assets

 

 

605

 

 

 

1,166

 

Total assets

 

$

313,801

 

 

$

400,115

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

5,827

 

 

$

603

 

Accrued compensation and related benefits

 

 

19,005

 

 

 

21,519

 

Accrued expenses and other current liabilities

 

 

13,459

 

 

 

16,227

 

Accrued warranty liability

 

 

3,712

 

 

 

3,620

 

Deferred revenue, current

 

 

11,727

 

 

 

8,662

 

Operating lease liabilities, current

 

 

1,593

 

 

 

1,318

 

Total current liabilities

 

 

55,323

 

 

 

51,949

 

Accrued interest

 

 

896

 

 

 

113

 

Deferred revenue

 

 

101

 

 

 

151

 

Operating lease liabilities

 

 

4,482

 

 

 

5,576

 

Term loans

 

 

130,113

 

 

 

96,336

 

Total liabilities

 

 

190,915

 

 

 

154,125

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2023 and 2022

 

 

 

 

 

 

Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2023 and 2022; 50,317 and 48,465 shares issued and outstanding as of December 31, 2023 and 2022, respectively

 

 

50

 

 

 

48

 

Additional paid-in capital

 

 

1,084,515

 

 

 

1,035,456

 

Accumulated other comprehensive loss

 

 

68

 

 

 

(564

)

Accumulated deficit

 

 

(961,747

)

 

 

(788,950

)

Total stockholders' equity

 

 

122,886

 

 

 

245,990

 

Total liabilities and stockholders' equity

 

$

313,801

 

 

$

400,115

 

 

 

 


 

Outset Medical, Inc.

Condensed Statements of Cash Flows

(in thousands)

(unaudited)

 

 

 

Years Ended December 31,

 

 

 

2023

 

 

2022

 

Net cash used in operating activities

 

$

(131,373

)

 

$

(145,729

)

Net cash provided by (used in) investing activities

 

 

83,026

 

 

 

(66,295

)

Net cash provided by financing activities

 

 

43,652

 

 

 

72,898

 

Net decrease in cash, cash equivalents and restricted cash

 

 

(4,695

)

 

 

(139,126

)

Cash, cash equivalents and restricted cash at beginning of the period

 

 

76,533

 

 

 

215,659

 

Cash, cash equivalents and restricted cash at end of the period (1)

 

$

71,838

 

 

$

76,533

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):

 

 

 

 

 

December 31,

 

 

2023

 

 

2022

 

Cash and cash equivalents

 

$

68,509

 

 

$

73,222

 

Restricted cash

 

 

3,329

 

 

 

3,311

 

Total cash, cash equivalents and restricted cash*

 

$

71,838

 

 

$

76,533

 

 

 

 

 

 

 

 

* The total cash, including restricted cash, cash equivalents and investment securities as of December 31, 2023 was $206.7 million; compared to $290.8 million as of December 31, 2022.

 

 

 

 

 


 

Appendix A

Outset Medical, Inc.

Results of Operations – Non-GAAP

(in thousands, except per share amounts)

(unaudited)

 

Reconciliation between GAAP and non-GAAP net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Years Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

GAAP net loss per share, diluted

 

$

(0.77

)

 

 

$

(0.86

)

 

 

$

(3.48

)

 

 

$

(3.38

)

 

Stock-based compensation expense

 

 

0.18

 

 

 

 

0.15

 

 

 

 

0.78

 

 

 

 

0.56

 

 

Non-GAAP net loss per share, diluted

 

$

(0.59

)

 

 

$

(0.71

)

 

 

$

(2.70

)

 

 

$

(2.82

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation between GAAP and non-GAAP net loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Years Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

GAAP net loss, diluted

 

$

(38,600

)

 

 

$

(41,444

)

 

 

$

(172,797

)

 

 

$

(162,956

)

 

Stock-based compensation expense

 

 

9,098

 

 

 

 

7,353

 

 

 

 

38,634

 

 

 

 

27,203

 

 

Non-GAAP net loss, diluted

 

$

(29,502

)

 

 

$

(34,091

)

 

 

$

(134,163

)

 

 

$

(135,753

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation between GAAP and non-GAAP results of operations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Years Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

GAAP gross profit

 

$

7,712

 

 

 

$

5,273

 

 

 

$

29,000

 

 

 

$

17,833

 

 

Stock-based compensation expense

 

 

424

 

 

 

 

208

 

 

 

 

1,805

 

 

 

 

701

 

 

Non-GAAP gross profit

 

$

8,136

 

 

 

$

5,481

 

 

 

$

30,805

 

 

 

$

18,534

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

 

25.3

 

%

 

 

16.5

 

%

 

 

22.2

 

%

 

 

15.5

 

%

Stock-based compensation expense

 

 

1.4

 

 

 

 

0.6

 

 

 

 

1.4

 

 

 

 

0.6

 

 

Non-GAAP gross margin

 

 

26.7

 

%

 

 

17.1

 

%

 

 

23.6

 

%

 

 

16.1

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP research and development expense

 

$

12,532

 

 

 

$

11,444

 

 

 

$

57,307

 

 

 

$

48,855

 

 

Stock-based compensation expense

 

 

(2,306

)

 

 

 

(1,960

)

 

 

 

(10,538

)

 

 

 

(6,845

)

 

Non-GAAP research and development expense

 

$

10,226

 

 

 

$

9,484

 

 

 

$

46,769

 

 

 

$

42,010

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP sales and marketing expense

 

$

22,194

 

 

 

$

23,631

 

 

 

$

96,232

 

 

 

$

89,482

 

 

Stock-based compensation expense

 

 

(2,511

)

 

 

 

(2,829

)

 

 

 

(12,419

)

 

 

 

(10,269

)

 

Non-GAAP sales and marketing expense

 

$

19,683

 

 

 

$

20,802

 

 

 

$

83,813

 

 

 

$

79,213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP general and administrative expense

 

$

10,339

 

 

 

$

10,022

 

 

 

$

45,231

 

 

 

$

40,515

 

 

Stock-based compensation expense

 

 

(3,857

)

 

 

 

(2,356

)

 

 

 

(13,872

)

 

 

 

(9,388

)

 

Non-GAAP general and administrative expense

 

$

6,482

 

 

 

$

7,666

 

 

 

$

31,359

 

 

 

$

31,127

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP total operating expense

 

$

45,065

 

 

 

$

45,097

 

 

 

$

198,770

 

 

 

$

178,852

 

 

Stock-based compensation expense

 

 

(8,674

)

 

 

 

(7,145

)

 

 

 

(36,829

)

 

 

 

(26,502

)

 

Non-GAAP total operating expense

 

$

36,391

 

 

 

$

37,952

 

 

 

$

161,941

 

 

 

$

152,350